BullTrends.com Announces Focus Alerts on – WFT, DRRX, TTNP, and CTRP


Investment Opinion

Share Tweet

BullTrends.com Announces Focus Alerts on – WFT, DRRX, TTNP, and CTRP

Wondering what your next move should be in the market? BullTrends.com can help lead the way. For free access to our complete stock reports, take a few minutes to register with us by clicking this link: http://www.bulltrends.com/ 

Weatherford International Ltd. (NYSE: WFT) – For an in-depth report on Weatherford International Ltd. follow: www.BullTrends.com/stockquote/WFT

Shares of Weatherford International Ltd. closed up 2.91% on about 19 million shares traded making it one of the most active stocks in the NYSE on Thursday. The stock’s average trading volume is around 7.5 million shares. The company has recently lowered its quarterly guidance to a range of $0.05 to $0.08, much lower than previously anticipated; and 2014 earnings of $1.10 to $1.20, beneath a previous $1.21 consensus.

DURECT Corporation (NASDAQ: DRRX) – For an in-depth report on DURECT Corporation follow: www.BullTrends.com/stockquote/DRRX

Shares of DRRX closed down 20.51% on Thursday with nearly 9.5 million shares traded. The stock was one of the biggest decliners on the NASDAQ. The big drop came after the company received a complete response letter from the Food and Drug Administration for Posidur after the closing bell last night. According to the press release from DURECT, Posidur, a direct-injection medication into surgical sites that acts as a painkiller, cannot be approved in its present form because "the [new drug application] does not contain sufficient information to demonstrate that Posidur is safe when used in the manner described in the proposed label."

Titan Pharmaceuticals Inc. (OTCBB: TTNP) – For an in-depth report on Titan Pharmaceuticals Inc. follow: www.BullTrends.com/stockquote/TTNP

Titan Pharmaceuticals shot up a modest 1.54% on Thursday with also a modest 75,000 shares traded. Though the company lacked significant news or much action, it did send out a promising press release back in December. The company announced the receipt of the official minutes (the "Minutes") from a Type C meeting with the U.S. Food and Drug Administration (FDA) on November 19, 2013 to discuss the Complete Response Letter (CRL) to its New Drug Application (NDA) for Probuphine®, an investigational subdermal implant for the maintenance treatment of opioid dependence in adult patients. Per the Minutes, the FDA emphasized its commitment to working with Titan and its partner, Braeburn Pharmaceuticals, to pursue a reasonable path to approval, and all parties agreed that seeking an indication in individuals stabilized on 8 mg/day or less of sublingual buprenorphine (SL BPN) may be a suitable approval pathway for Probuphine.

Ctrip.com International Ltd. (NASDAQ: CTRP) – For an in-depth report on Ctrip.com International Ltd. follow: www.BullTrends.com/stockquote/CTRP

Shares of Ctrip.com closed up 10.23% on about 23 million shares on Thursday. The stock was one of the biggest advancers on the NASDAQ. The big jump came after the Chinese travel specialist turned in better-than-expected fourth-quarter results. Quarterly revenue rose 31% year over year, to $238 million, which translated to adjusted earnings of $0.39 per share. By contrast, analysts were only looking for earnings of $0.23 per share on sales of $226.76 million.


Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.